Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 1.023
Filtrar
1.
Virchows Arch ; 478(2): 153-190, 2021 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-33604759

RESUMO

A European consensus conference on endometrial carcinoma was held in 2014 to produce multidisciplinary evidence-based guidelines on selected questions. Given the large body of literature on the management of endometrial carcinoma published since 2014, the European Society of Gynaecological Oncology (ESGO), the European SocieTy for Radiotherapy & Oncology (ESTRO) and the European Society of Pathology (ESP) jointly decided to update these evidence-based guidelines and to cover new topics in order to improve the quality of care for women with endometrial carcinoma across Europe and worldwide. ESGO/ESTRO/ESP nominated an international multidisciplinary development group consisting of practicing clinicians and researchers who have demonstrated leadership and expertise in the care and research of endometrial carcinoma (27 experts across Europe). To ensure that the guidelines are evidence-based, the literature published since 2014, identified from a systematic search was reviewed and critically appraised. In the absence of any clear scientific evidence, judgment was based on the professional experience and consensus of the development group. The guidelines are thus based on the best available evidence and expert agreement. Prior to publication, the guidelines were reviewed by 191 independent international practitioners in cancer care delivery and patient representatives. The guidelines comprehensively cover endometrial carcinoma staging, definition of prognostic risk groups integrating molecular markers, pre- and intra-operative work-up, fertility preservation, management for early, advanced, metastatic, and recurrent disease and palliative treatment. Principles of radiotherapy and pathological evaluation are also defined.


Assuntos
Carcinoma/terapia , Neoplasias do Endométrio/terapia , Oncologia/normas , Biomarcadores Tumorais/genética , Biópsia/normas , Carcinoma/genética , Carcinoma/patologia , Neoplasias do Endométrio/genética , Neoplasias do Endométrio/patologia , Medicina Baseada em Evidências/normas , Feminino , Humanos , Técnicas de Diagnóstico Molecular/normas , Estadiamento de Neoplasias/normas , Valor Preditivo dos Testes , Medição de Risco , Fatores de Risco , Resultado do Tratamento
2.
Int J Mol Sci ; 22(3)2021 Jan 26.
Artigo em Inglês | MEDLINE | ID: mdl-33530491

RESUMO

Oral cancer is one of the most common cancers worldwide. Despite easy access to the oral cavity and significant advances in treatment, the morbidity and mortality rates for oral cancer patients are still very high, mainly due to late-stage diagnosis when treatment is less successful. Oral cancer has also been found to be the most expensive cancer to treat in the United States. Early diagnosis of oral cancer can significantly improve patient survival rate and reduce medical costs. There is an urgent unmet need for an accurate and sensitive molecular-based diagnostic tool for early oral cancer detection. Fourier transform infrared spectroscopy has gained increasing attention in cancer research due to its ability to elucidate qualitative and quantitative information of biochemical content and molecular-level structural changes in complex biological systems. The diagnosis of a disease is based on biochemical changes underlying the disease pathology rather than morphological changes of the tissue. It is a versatile method that can work with tissues, cells, or body fluids. In this review article, we aim to summarize the studies of infrared spectroscopy in oral cancer research and detection. It provides early evidence to support the potential application of infrared spectroscopy as a diagnostic tool for oral potentially malignant and malignant lesions. The challenges and opportunities in clinical translation are also discussed.


Assuntos
Biomarcadores Tumorais , Neoplasias Bucais/diagnóstico , Espectroscopia de Infravermelho com Transformada de Fourier , Animais , Suscetibilidade a Doenças , Detecção Precoce de Câncer/métodos , Detecção Precoce de Câncer/normas , Histocitoquímica , Humanos , Neoplasias Bucais/etiologia , Neoplasias Bucais/metabolismo , Gradação de Tumores/métodos , Gradação de Tumores/normas , Estadiamento de Neoplasias/métodos , Estadiamento de Neoplasias/normas , Transdução de Sinais , Espectroscopia de Infravermelho com Transformada de Fourier/métodos , Análise Espectral/métodos , Análise Espectral/normas , Microambiente Tumoral
3.
J Surg Oncol ; 123(4): 891-903, 2021 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-33434341

RESUMO

OBJECTIVE: To explore the prognostic significance of tumor deposits (TDs), isolated tumor foci lacking residual lymph nodes, in esophageal cancer (EC). METHODS: A retrospective review of patients with EC undergoing esophagectomy between 2005 and 2017 was conducted. The prognostic value of TD was evaluated using a Cox regression model. Patients from different sources and periods were split into discovery and validation sets. A propensity score matching model was used in the validation set to reduce the confounding bias. The impact of TD on the TNM classification system was evaluated. RESULTS: The discovery and validation sets included 179 and 2875 patients, respectively. Propensity-matched patients with and without TDs were constructed in the validation set with 132 patients in each group. Overall survival (p < .001 and p = .004, respectively) and disease-free survival (p < .001 and p = .019, respectively) were both decreased in TD positive patients in the discovery set and propensity-matched groups of validation set. Classifying patients with TDs into pN3 stage improved the discriminative power of the current TNM staging system. CONCLUSIONS: TD is an independent prognostic factor for EC. The inclusion of TD in the TNM staging system may upstage appropriate patients to help guide therapy, and future studies are warranted.


Assuntos
Adenocarcinoma/patologia , Neoplasias Esofágicas/patologia , Esofagectomia/mortalidade , Linfonodos/patologia , Estadiamento de Neoplasias/normas , Adenocarcinoma/cirurgia , Adulto , Idoso , Idoso de 80 Anos ou mais , Neoplasias Esofágicas/cirurgia , Extensão Extranodal , Feminino , Seguimentos , Humanos , Linfonodos/cirurgia , Masculino , Pessoa de Meia-Idade , Prognóstico , Estudos Retrospectivos , Taxa de Sobrevida
4.
J Surg Oncol ; 123(4): 1099-1108, 2021 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-33333592

RESUMO

BACKGROUND AND OBJECTIVES: To examine the utility of a 3-tier schema (≤5 cm, 5.1-10 cm, and > 10 cm) in determining characteristics and survival in Stage I uterine leiomyosarcoma. METHODS: This retrospective observational study queried the National Cancer Institute's Surveillance, Epidemiology, and End Result Program from 1988 to 2016. Surgically treated stage I uterine leiomyosarcomas with known tumor size were examined (N = 2217). Trends, characteristics, and survival were assessed based on tumor size. RESULTS: The most common tumor size was 5.1-10 cm (45.7%) followed by >10 cm (35.0%) and ≤5 cm (19.4%). Tumor size-shift occurred during the study period; the percentage of tumor size >10 cm increased from 12.9% to 44.5% and the groups with smaller tumor sizes decreased (p < .001). In weighted models, 5-year overall survival rates ranged from 49.9% to 71.6% in the 3-tier system and 55.2%-70.6% in the 2-tier system: the absolute difference was larger in the 3-tier system (21.7% vs. 15.4%). In the 3-tier system, all-cause mortality risk of tumor size >10 cm versus ≤5 cm nearly doubled (hazard ratio 1.96, 95% confidence interval 1.78-2.16). CONCLUSION: In the past decades, tumors of stage I uterine leiomyosarcoma have become larger. Our study suggests that a tumor size-based 3-tier staging system may be useful to differentiate survival in stage I uterine leiomyosarcoma.


Assuntos
Histerectomia/mortalidade , Leiomiossarcoma/patologia , Estadiamento de Neoplasias/normas , Neoplasias Uterinas/patologia , Feminino , Seguimentos , Humanos , Leiomiossarcoma/cirurgia , Pessoa de Meia-Idade , Estudos Retrospectivos , Taxa de Sobrevida , Resultado do Tratamento , Neoplasias Uterinas/cirurgia
5.
Lancet Haematol ; 8(1): e67-e79, 2021 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-33357485

RESUMO

PET using 18F-fluorodeoxyglucose is central to the management of patients with Hodgkin lymphoma, and PET-adapted strategies have facilitated major improvements in overall survival. Although unmet needs include addressing fertility preservation, cardiovascular health, and survivorship issues, along with a need for better cure rates in the older patient, the improved survival of most patients with Hodgkin lymphoma globally is a triumph of the complementary approaches and collaboration of many cooperative groups in the study of PET-guided therapy. The optimal strategy for this highly curable lymphoma, however, remains a topic of intense discussion and polarises opinion among clinicians. In this Review, we seek not to debate the many controversies that exist but to better inform the treating haematologist to assist in navigating a patient-specific approach. Focusing primarily on phase 3 studies, we chart the changes in management based on the most relevant technological advance in the past decade, the standardisation of PET-CT for staging, interim, and end-of-treatment response assessment of Hodgkin lymphoma.


Assuntos
Doença de Hodgkin/diagnóstico por imagem , Doença de Hodgkin/mortalidade , Doença de Hodgkin/terapia , Tomografia Computadorizada com Tomografia por Emissão de Pósitrons/normas , Intervalo Livre de Doença , Humanos , Estadiamento de Neoplasias/normas , Taxa de Sobrevida
6.
Am J Surg Pathol ; 44(10): 1381-1388, 2020 10.
Artigo em Inglês | MEDLINE | ID: mdl-32931163

RESUMO

The eighth edition of the American Joint Committee on Cancer (AJCC) Staging Manual attempts to address ambiguity in the pT category assignment for colon cancer from prior editions. Despite modifications, the distinction between the pT3 and pT4a categories continues to be a source of diagnostic confusion. In this study, we assessed interobserver agreement among pathologists from different institutions in the application of AJCC eighth edition criteria for categorizing deeply invasive colonic adenocarcinomas. We identified morphologic patterns that produce diagnostic confusion. We assessed 47 colon cancers that closely approached the serosal surface. Six pathologists with interest in gastrointestinal pathology and 4 focused in other subspecialties classified each case as pT3 or pT4a, based on examination of low-magnification and high-magnification images of the most deeply invasive area. Interobserver agreement was assessed using Fleiss' κ. Cases displayed 3 morphologic patterns at the advancing tumor edge, namely, (1) continuous invasion through an inflammatory focus, (2) pushing border, and (3) infiltrative glands and cell clusters with serosal reaction. Gastrointestinal pathologists achieved slight (κ=0.21) or moderate (κ=0.46) and (κ=0.51) agreement in each category, whereas agreement among nongastrointestinal pathologist was fair (0.31) and (0.39), or moderate (0.57) for each category, respectively. In 10 (21%) cases, the distinction between pT3 and pT4a would have changed the overall clinical stage. We conclude that histologic criteria for serosal penetration is a persistent source of diagnostic ambiguity for gastrointestinal and general pathologists in the pT categorization of colon cancers. Clarification of these criteria will help ensure uniform reporting of pathologic and clinical stage.


Assuntos
Adenocarcinoma/patologia , Neoplasias do Colo/patologia , Estadiamento de Neoplasias/métodos , Adenocarcinoma/classificação , Adulto , Idoso , Idoso de 80 Anos ou mais , Neoplasias do Colo/classificação , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Estadiamento de Neoplasias/normas , Variações Dependentes do Observador , Adulto Jovem
7.
Zhonghua Wai Ke Za Zhi ; 58(8): 614-618, 2020 Aug 01.
Artigo em Chinês | MEDLINE | ID: mdl-32727193

RESUMO

Objective: To compare the accuracy of abdominal enhanced CT and endoscopic ultrasound in the staging of gastric cancer after neoadjuvant chemotherapy (yc stage). Methods: Clinic data of 86 locally advanced gastric cancer patients admitted in Gastrointestinal Cancer Center, Peking University Cancer Hospital & Institute from April 2015 to November 2017 were analyzed retrospectively. Totally 86 patients completed both abdominal enhanced CT and endoscopic ultrasound after neoadjuvant chemotherapy. There were 60 males and 26 females, aged (57.8±9.7) years (range: 32 to 76 years). The diagnostic accuracy of abdominal enhanced CT and endoscopic ultrasound for yc stage were calculated by the area under the multiclass receiver operation characteristic curve (M-AUC), retrospectively. McNemar test was used to compared the diagnostic sensitivity. Results: The M-AUC of ycT stage evaluated by abdominal enhanced CT (CT-ycT stage) and by endoscopic ultrasound (EUS-ycT stage) was 0.614 and 0.704, respectively. For middle and lower gastric cancer, the M-AUC of CT-ycT stage was 0.599 and 0.613, respectively, while EUS-ycT stage was 0.558 and 0.709, respectively. For tumor in the lesser and non-lesser curvature, the M-AUC of CT-ycT stage was 0.630 and 0.607, respectively, while EUS-ycT stage was 0.616 and 0.749, respectively. For patients in CT-ycT1-CT-ycT4, there was no statistically significant difference in the sensitivity between CT-ycT stage and EUS-ycT stage (2/18, 2/15, 52.8%(19/36), 8/13 vs. 0, 4/15, 55.6%(20/36), 7/13; χ(2)=2.00, P=0.157; χ(2)=2.00, P=0.157; χ(2)=0.08, P=0.782; χ(2)=0.33, P=0.564). The M-AUC of ycN stage evaluated by abdominal enhanced CT (CT-ycN stage) was 0.654, while ycN stage evaluated by endoscopic ultrasound (EUS-ycN stage) was 0.533. For patients in CT-ycN0, there was statistically significant difference in the sensitivity between CT-ycN stage and EUS-ycN stage (12.7%(7/55) vs. 5.5%(3/55); χ(2)=4.00, P=0.046). For patients in CT-ycN1, N2, and N3, there was no statistically significant difference in the sensitivity between CT-ycN stage and EUS-ycN stage (2/19, 1/10, 0 vs. 1/19, 1/10, 0; χ(2)=1.00, P=0.317; the other P cannot be estimated). Conclusions: There was no significant difference between the diagnostic efficacy of abdominal enhanced CT and endoscopic ultrasound for yc stage of gastric cancer. Considering the invasiveness of ultrasound gastroscopy, it should not be recommend for patients after neoadjuvant chemotherapy routinely.


Assuntos
Antineoplásicos/administração & dosagem , Endossonografia , Estadiamento de Neoplasias/métodos , Neoplasias Gástricas/diagnóstico por imagem , Neoplasias Gástricas/cirurgia , Tomografia Computadorizada por Raios X , Adulto , Idoso , Endossonografia/métodos , Endossonografia/normas , Feminino , Gastroscopia , Humanos , Masculino , Pessoa de Meia-Idade , Terapia Neoadjuvante , Estadiamento de Neoplasias/normas , Reprodutibilidade dos Testes , Estudos Retrospectivos , Neoplasias Gástricas/tratamento farmacológico , Tomografia Computadorizada por Raios X/métodos , Tomografia Computadorizada por Raios X/normas
8.
Anticancer Res ; 40(6): 3401-3410, 2020 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-32487637

RESUMO

BACKGROUND/AIM: In local staging of gastric adenocarcinoma CT is the modality of choice. Less frequently used in a few selected patients is echo-endoscopy. Aim of this study was to evaluate the accuracy of hydro-multidetector-computed tomography (hydro-MDCT) in the evaluation of gastric adenocarcinomas with subsequent surgical and histopathological correlation to select cases for echo-endoscopy. PATIENTS AND METHODS: A total of 65 patients with gastric adenocarcinomas, diagnosed by endoscopy and biopsy, underwent contrast-enhanced hydro-MDCT with subsequent tumor, nodes, metastases (TNM) classification. The distension of the gastric lumen was obtained after the oral administration of 500 ml of water. RESULTS: Hydro-MDCT always detected gastric cancer and in 49/65 patients the assessment of T-parameter was identical to the histopathological results (accuracy: 75%). We found overstaging in 12 and understaging in 4 cases. N-parameter with MDCT was in agreement with histo-pathology in 69%of patients; in metastatic disease hydro-MDCT had an accuracy of 99%. Hydro-MDCT has proven to be a reliable diagnostic technique in evaluating gastric cancer T3-T4 stages in comparison to T1 and T2: in defining T2-stage we found the highest number of errors (37%). CONCLUSION: Hydro-MDCT is a reliable technique in the preoperative staging of gastric adenocarcinoma. Echo-endoscopy could be particularly useful in doubtful cases to evaluate the muscularis propria infiltration (T2 vs. T3) and characterize the peri-gastric lymph nodes.


Assuntos
Tomografia Computadorizada Multidetectores , Estadiamento de Neoplasias , Neoplasias Gástricas/diagnóstico por imagem , Neoplasias Gástricas/patologia , Adulto , Idoso , Idoso de 80 Anos ou mais , Biópsia , Meios de Contraste , Endossonografia/métodos , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Tomografia Computadorizada Multidetectores/métodos , Tomografia Computadorizada Multidetectores/normas , Estadiamento de Neoplasias/métodos , Estadiamento de Neoplasias/normas , Seleção de Pacientes , Cuidados Pré-Operatórios , Estudos Retrospectivos , Neoplasias Gástricas/cirurgia
9.
Pediatr Blood Cancer ; 67(6): e28303, 2020 06.
Artigo em Inglês | MEDLINE | ID: mdl-32301558

RESUMO

BACKGROUND: Cancer stage is a determinant of survival of childhood central nervous system (CNS) cancers and could help the interpretation of survival variability among countries. Consensus guidelines to stage childhood malignancies in population cancer registries ("Toronto Childhood Cancer Stage Guidelines") have been recently proposed with the goal of data comparability. Indeed, stage is not systematically recorded in all registries and, when it is, different classification systems are used. We applied the Toronto Childhood Cancer Stage Guidelines to CNS cancer cases of three population-based cancer registries with the aim of evaluating the feasibility of staging this type of cancer and the critical points in the classification of CNS tumors. PROCEDURES: The Toronto Childhood Cancer Stage Guidelines were applied to 175 CNS patients, diagnosed from January 1, 2002 to December 31, 2014 in three cancer registries in Italy, and the percentage of cases that could be staged was assessed. RESULTS: One hundred eight of 126 (86%) medulloblastomas and other embryonal CNS cancers and 22 of 49 (45%) ependymomas were staged. Using these guidelines, survival of children with localized tumors could be discriminated from that of children with metastatic disease. CONCLUSIONS: The use of the Toronto Childhood Cancer Stage Guidelines is feasible for staging medulloblastoma in Italian population-based cancer registries, whereas it is more difficult for ependymomas. In Italy, cerebrospinal fluid examination, one of the decisive tests to stage CNS tumors, is not routinely performed as a first-line diagnosis procedure in ependymoma pediatric patients. A similar exercise by a larger number of cancer registries in different countries could suggest improvements in the childhood cancer staging system.


Assuntos
Neoplasias do Sistema Nervoso Central/mortalidade , Neoplasias do Sistema Nervoso Central/patologia , Estadiamento de Neoplasias/normas , Guias de Prática Clínica como Assunto/normas , Sistema de Registros/estatística & dados numéricos , Adolescente , Adulto , Criança , Pré-Escolar , Gerenciamento de Dados , Feminino , Seguimentos , Humanos , Lactente , Recém-Nascido , Masculino , Prognóstico , Programa de SEER , Taxa de Sobrevida , Adulto Jovem
10.
Ann R Coll Surg Engl ; 102(6): 429-436, 2020 Jul.
Artigo em Inglês | MEDLINE | ID: mdl-32326728

RESUMO

INTRODUCTION: In breast cancer, early identification of distant metastasis changes management. Current guidelines recommend radiological staging in patients with a preoperative positive axilla; no guidelines address a preoperative negative axilla with subsequent positive sentinel lymph node biopsy. This study investigates whether current guidelines adequately identify distant metastasis in a positive sentinel lymph node biopsy population that had radiological staging. MATERIALS AND METHODS: Patients diagnosed with primary breast cancer between 1 January 2013 and 1 October 2017 with a positive sentinel lymph node biopsy and subsequent radiological staging from a single unit were included. A systematic search identified relevant guideline criteria, against which patients were audited. RESULTS: A total of 330 patients with positive sentinel lymph node biopsy were identified; 227 (69%) had radiological staging postoperatively with computed tomography (5.3%), bone scan (2.6%) and both (92%) which identified 8/227 (3.5%) patients had distant metastasis. Patients with distant metastasis (DMp) compared with those without distant metastasis (NDMp) were associated with poorly differentiated tumours (DMp 62% vs NDMp 28%; p = 0.037), high-grade ductal carcinoma in situ (DMp 75% vs NDMp 39%; p = 0.043) and increased mean invasive tumour size (DMp 37mm vs NDMp 24mm; p = 0.014). Binomial logistic regression did not identify any characteristics to predict distant metastasis in staged patients (chi-squared p = 0.162). Two guidelines used postoperative results to inform radiological staging decision; 68/227 (30%) of staged patients met these guideline criteria, five of eight patients with distant metastasis did not meet current guideline criteria for radiological staging. DISCUSSION: Over 50% of patients with distant metastasis did not meet current guideline criteria for radiological staging and would have remained undiagnosed if current guidelines were followed. This study had an acceptable detection rate of 3.5% for distant metastasis. We therefore recommend radiological staging in all patients with positive sentinel lymph node biopsy.


Assuntos
Neoplasias da Mama/diagnóstico , Carcinoma Intraductal não Infiltrante/diagnóstico , Metástase Linfática/diagnóstico , Guias de Prática Clínica como Assunto , Biópsia de Linfonodo Sentinela/normas , Tomografia Computadorizada por Raios X/normas , Adulto , Idoso , Idoso de 80 Anos ou mais , Axila , Neoplasias da Mama/patologia , Neoplasias da Mama/cirurgia , Carcinoma Intraductal não Infiltrante/patologia , Carcinoma Intraductal não Infiltrante/cirurgia , Tomada de Decisão Clínica/métodos , Feminino , Humanos , Modelos Logísticos , Mastectomia/estatística & dados numéricos , Pessoa de Meia-Idade , Estadiamento de Neoplasias/métodos , Estadiamento de Neoplasias/normas , Seleção de Pacientes , Período Pós-Operatório , Cuidados Pré-Operatórios/métodos , Cuidados Pré-Operatórios/normas , Cuidados Pré-Operatórios/estatística & dados numéricos , Linfonodo Sentinela/diagnóstico por imagem , Linfonodo Sentinela/patologia , Biópsia de Linfonodo Sentinela/estatística & dados numéricos , Tomografia Computadorizada por Raios X/estatística & dados numéricos
11.
Medicine (Baltimore) ; 99(9): e19314, 2020 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-32118758

RESUMO

BACKGROUND: Ruling out distant metastases, non-small cell lung cancer (NSCLC)treatment depends on the results of mediastinal node staging (N staging). Several diagnostic methods play central roles in mediastinal N staging. This study is intended to evaluate the existing diagnostic methods and report quality, and to search for the best method for staging mediastinal lymph nodes. METHODS: We searched PubMed, Embase, and the Cochrane Library to identify relevant studies, including randomized controlled trials and retrospective studies. These studies report the application of computed tomography, positron emission tomography-computed tomography, magnetic resonance imaging, endobronchial ultrasound, and mediastinoscopy in the diagnosis of mediastinal lymph node staging of NSCLC. The quality of the literature was assessed using the Quality Assessment of Diagnostic Accuracy Study 2. The true positive, false positive, true negative, and false negative of each study was extracted. The corresponding sensitivity, specificity, and other indicators were calculated and the Summary Receiver Operating curve was established. Then, head-to-head and indirect comparison meta-analyses will be conducted. RESULTS: The results of this study will be published in a peer-reviewed journal. CONCLUSION: This study will provide basis for mediastinal lymph node staging of non-small cell lung cancer. PROSPERO REGISTRATION NUMBER: CRD42019145667.


Assuntos
Carcinoma Pulmonar de Células não Pequenas/diagnóstico , Diagnóstico por Imagem/normas , Linfonodos/fisiopatologia , Estadiamento de Neoplasias/normas , Idoso , Carcinoma Pulmonar de Células não Pequenas/fisiopatologia , Protocolos Clínicos , Diagnóstico por Imagem/métodos , Endoscopia/métodos , Endoscopia/normas , Feminino , Humanos , Linfonodos/diagnóstico por imagem , Imagem por Ressonância Magnética/métodos , Imagem por Ressonância Magnética/normas , Masculino , Mediastinoscopia/métodos , Mediastinoscopia/normas , Pessoa de Meia-Idade , Estadiamento de Neoplasias/métodos , Tomografia Computadorizada com Tomografia por Emissão de Pósitrons/métodos , Tomografia Computadorizada com Tomografia por Emissão de Pósitrons/normas , Tomografia Computadorizada por Raios X/métodos , Tomografia Computadorizada por Raios X/normas , Ultrassonografia/métodos , Ultrassonografia/normas
12.
Eur J Cancer ; 128: 60-82, 2020 03.
Artigo em Inglês | MEDLINE | ID: mdl-32113941

RESUMO

Invasive cutaneous squamous cell carcinoma (cSCC) is one of the most common cancers in the white populations, accounting for 20% of all cutaneous malignancies. Factors implicated in cSCC etiopathogenesis include ultraviolet radiation exposure and chronic photoaging, age, male sex, immunosuppression, smoking and genetic factors. A collaboration of multidisciplinary experts from the European Dermatology Forum (EDF), the European Association of Dermato-Oncology (EADO) and the European Organisation of Research and Treatment of Cancer (EORTC) was formed to update recommendations on cSCC classification, diagnosis, risk stratification, staging and prevention, based on current literature, staging systems and expert consensus. Common cSCCs are typically indolent tumors, and most have a good prognosis with 5-year cure rates of greater than 90%, and a low rate of metastases (<4%). Further risk stratification into low-risk or high-risk common primary cSCC is recommended based on proposed high-risk factors. Advanced cSCC is classified as locally advanced (lacSCC), and metastatic (mcSCC) including locoregional metastatic or distant metastatic cSCC. Current systems used for staging include the American Joint Committee on Cancer (AJCC) 8th edition, the Union for International Cancer Control (UICC) 8th edition, and Brigham and Women's Hospital (BWH) system. Physical examination for all cSCCs should include total body skin examination and clinical palpation of lymph nodes, especially of the draining basins. Radiologic imaging such as ultrasound of the regional lymph nodes, magnetic resonance imaging (MRI), computed tomography (CT), positron emission tomography-computed tomography (PET-CT) scans are recommended for staging of high-risk cSCC. Sentinel lymph node biopsy is currently not recommended. Nicotinamide, oral retinoids, and topical 5-FU have been used for the chemoprevention of subsequent cSCCs in high-risk patients but are not routinely recommended. Education about sun protection measures including reducing sun exposure, use of protective clothing, regular use of sunscreens and avoidance of artificial tanning, is recommended.


Assuntos
Carcinoma de Células Escamosas/diagnóstico , Consenso , Dermatologia/normas , Oncologia/normas , Neoplasias Cutâneas/diagnóstico , Carcinoma de Células Escamosas/etiologia , Carcinoma de Células Escamosas/patologia , Carcinoma de Células Escamosas/prevenção & controle , Humanos , Linfonodos/diagnóstico por imagem , Imagem por Ressonância Magnética/normas , Estadiamento de Neoplasias/normas , Educação de Pacientes como Assunto/normas , Tomografia Computadorizada com Tomografia por Emissão de Pósitrons/normas , Roupa de Proteção/normas , Medição de Risco/normas , Pele/diagnóstico por imagem , Pele/patologia , Neoplasias Cutâneas/etiologia , Neoplasias Cutâneas/patologia , Neoplasias Cutâneas/prevenção & controle , Sociedades Médicas/normas , Luz Solar/efeitos adversos , Protetores Solares/administração & dosagem , Ultrassonografia/normas
13.
Eur J Cancer ; 128: 83-102, 2020 03.
Artigo em Inglês | MEDLINE | ID: mdl-32113942

RESUMO

In order to update recommendations on treatment, supportive care, education and follow-up of patients with invasive cutaneous squamous cell carcinoma (cSCC), a multidisciplinary panel of experts from the European Dermatology Forum, the European Association of Dermato-Oncology and the European Organization of Research and Treatment of Cancer was formed. Recommendations were based on evidence-based literature review, guidelines and expert consensus. Treatment recommendations are presented for common primary cSCC (low risk, high risk), locally advanced cSCC, regional metastatic cSCC (operable or inoperable) and distant metastatic cSCC. For common primary cSCC (the most frequent cSCC type), first-line treatment is surgical excision with postoperative margin assessment or microscopically controlled sugery. Safety margins containing clinical normal-appearing tissue around the tumour during surgical excision and negative margins as reported in the pathology report are necessary to minimise the risk of local recurrence and metastasis. In case of positive margins, a re-excision shall be done, for operable cases. Lymph node dissection is recommended for cSCC with cytologically or histologically confirmed regional nodal involvement. Radiotherapy should be considered as curative treatment for inoperable cSCC, or for non-surgical candidates. Anti-PD-1 antibodies are the first-line systemic treatment for patients with metastatic or locally advanced cSCC who are not candidates for curative surgery or radiation, with cemiplimab being the first approved systemic agent for advanced cSCC by the Food and Drug Administration/European Medicines Agency. Second-line systemic treatments for advanced cSCC include epidermal growth factor receptor inhibitors (cetuximab) combined with chemotherapy or radiation therapy. Multidisciplinary board decisions are mandatory for all patients with advanced disease who require more than surgery. Patients should be engaged with informed decisions on management and be provided with best supportive care to optimise symptom management and improve quality of life. Frequency of follow-up visits and investigations for subsequent new cSCC depend on underlying risk characteristics.


Assuntos
Carcinoma de Células Escamosas/terapia , Procedimentos Cirúrgicos Dermatológicos/normas , Dermatologia/normas , Oncologia/normas , Neoplasias Cutâneas/terapia , Assistência ao Convalescente/normas , Anticorpos Monoclonais Humanizados/uso terapêutico , Antineoplásicos Imunológicos/uso terapêutico , Carcinoma de Células Escamosas/diagnóstico , Carcinoma de Células Escamosas/etiologia , Carcinoma de Células Escamosas/patologia , Quimiorradioterapia/métodos , Quimiorradioterapia/normas , Tomada de Decisão Clínica , Consenso , Humanos , Excisão de Linfonodo , Linfonodos/diagnóstico por imagem , Linfonodos/patologia , Linfonodos/cirurgia , Margens de Excisão , Estadiamento de Neoplasias/normas , Cuidados Paliativos/normas , Equipe de Assistência ao Paciente/normas , Educação de Pacientes como Assunto/normas , Pele/diagnóstico por imagem , Pele/patologia , Neoplasias Cutâneas/diagnóstico , Neoplasias Cutâneas/etiologia , Neoplasias Cutâneas/patologia , Sociedades Médicas/normas , Luz Solar/efeitos adversos
14.
Medicina (Kaunas) ; 56(3)2020 Mar 13.
Artigo em Inglês | MEDLINE | ID: mdl-32183080

RESUMO

Background and objectives: With improved diagnostic means of early breast cancer, the percentage of cases with metastasis in axillary lymph nodes has decreased from 50%-75% to 15%-30%. Lymphadenectomy and sentinel lymph node biopsy are not treatment procedures, as they aim at axillary nodal staging in breast cancer. Being surgical interventions, they can lead to various complications. Therefore, recently much attention has been paid to the identification of non-invasive methods for axillary nodal staging. In many countries, ultrasound is a first-line method to evaluate axillary lymph node status. The aim of this study was to evaluate the prognostic value of ultrasound in detecting intact axillary lymph nodes and to assess the accuracy of ultrasound in detecting a heavy nodal disease burden. The additional objective was to evaluate patients' and tumor characteristics leading to false-negative results. Materials and Methods: A total of 227 women with newly diagnosed pT1 breast cancer were included to this prospective study conducted at the Breast Surgery Unit, Clinic of Surgery, Hospital of Lithuanian University of Health Sciences Kauno Klinikos, between May 1, 2016, and May 31, 2018. All patients underwent preoperative axillary ultrasound examination. Ultrasound data were compared with the results of histological examination. The accuracy and true-negative rate of ultrasound were calculated. The reasons of false-negative results were analyzed. Results: Of the 189 patients who had normally appearing axillary lymph nodes on preoperative ultrasound (PAUS-negative), 173 (91.5%) patients were also confirmed to have intact axillary lymph nodes (node-negative) by histological examination after surgery. The accuracy and the negative predictive value of ultrasound examination were 84.1% and 91.5%, respectively. In ≥3 node-positive cases, the accuracy and the negative predictive value increased to 88.7% and 98.3%, respectively. In total, false-negative results were found in 8.5% of the cases (n = 16); in the PAUS-negative group, false-negative results were recorded only in 1.6% of the cases (n = 3). The results of PAUS and pathological examination differed significantly between patients without and with lymphovascular invasion (LV0 vs. LV1, p < 0.001) as well as those showing no human epidermal growth factor receptor 2 (HER2) expression and patients with weakly or strongly expressed HER2 (HER2(0) vs. HER2(1), p = 0.024). Paired comparisons revealed that the true-negative rate was significantly different between the LV0 and LV1 groups (91% vs. 66.7%, p < 0.05), and the false-negative rate was statistically significant different between the HER2(0) and HER2(1) groups (10.5% vs. 1.2%, p < 0.05). Evaluation of other characteristics showed both the groups to be homogenous. Conclusions: Negative axillary ultrasound excluded axillary metastatic disease in 91.5% of the patients. PAUS had an accuracy of 88.7% in detecting a heavy nodal disease burden. With the absence of lymphovascular invasion (LV0), we can rely on PAUS examination that axillary lymph nodes are intact (PAUS-negative), and this patients' group could avoid sentinel lymph node biopsy. Patients without HER2 expression are at a greater likelihood of false-negative results; therefore, the findings of ultrasound that axillary lymph nodes are intact (PAUS-negative results) should be interpreted with caution.


Assuntos
Neoplasias da Mama/diagnóstico por imagem , Biópsia de Linfonodo Sentinela/métodos , Fatores de Tempo , Ultrassonografia/métodos , Adulto , Idoso , Axila/diagnóstico por imagem , Axila/fisiopatologia , Neoplasias da Mama/diagnóstico , Neoplasias da Mama/patologia , Feminino , Humanos , Lituânia , Pessoa de Meia-Idade , Estadiamento de Neoplasias/métodos , Estadiamento de Neoplasias/normas , Estadiamento de Neoplasias/estatística & dados numéricos , Período Pré-Operatório , Biópsia de Linfonodo Sentinela/normas , Biópsia de Linfonodo Sentinela/estatística & dados numéricos , Ultrassonografia/normas , Ultrassonografia/estatística & dados numéricos
15.
Rev. patol. respir ; 23(1): 9-14, ene.-mar. 2020. tab
Artigo em Espanhol | IBECS | ID: ibc-191888

RESUMO

OBJETIVO. Estudiar cómo de cuantificables son los indicadores de calidad propuestos por Neumomadrid para el diagnóstico y la estadificación del cáncer de pulmón y analizar mediante su recogida la asistencia recibida por pacientes con cáncer de pulmón en una muestra de hospitales de la Comunidad de Madrid. MATERIAL Y MÉTODO: Estudio retrospectivo en el que se analizaron todos los casos de cáncer de pulmón diagnosticados en 2017 en 5 hospitales pertenecientes al Servicio Madrileño de Salud. Se recogieron el sexo, la edad, la estirpe tumoral y el estadio TNM, y se analizaron siete de los indicadores propuestos por Neumomadrid para el diagnóstico y la estadificación del cáncer de pulmón. RESULTADOS: Se recogieron 302 casos, 80 (26,5%) mujeres y 222 (73,5%) varones, con una mediana de edad de 69 años (rango: 41-89). La estirpe más frecuente fue adenocarcinoma. El 27,5% presentaban un estadio III, y el 56% un estadio IV. Se pudieron recoger 1.004 indicadores de los 1.020 aplicables (98%). Solo se alcanzó el estándar de calidad en el indicador detección de dianas terapéuticas. Se observa variabilidad importante entre hospitales. CONCLUSIONES: Los indicadores de calidad propuestos por Neumomadrid para el diagnóstico y estadificación del cáncer de pulmón son cuantificables. Existe espacio para la mejora en la atención a estos pacientes


OBJECTIVE: Study how measurable are the quality indicators proposed by Neumomadrid for the diagnosis and staging of lung cancer and analyse lung cancer care in a sample of hospitals in Madrid. METHODS: Retrospective study analysing all lung cancer cases diagnosed during 2017 in 5 hospitals from the Servicio Madrileño de Salud. Sex, age, histology and TNM stage were collected, and 7 of the quality indicators proposed by Neumomadrid for the diagnosis and staging of lung cancer were analysed. RESULTS: 302 cases were collected, 80 (26.5%) women and 222 (73.5%) men, with a median age of 69 years (range: 41-89). Adenocarcinoma was the most common histology. Twenty-seven percent had a stage III disease, and 56% a stage IV. One thousand and four indicators out of 1020 were collected (98%). The quality standard was achieved only for the detection of therapeutic targets. Important variability across hospitals is observed. CONCLUSIONS: Quality indicators proposed by Neumomadrid for the diagnosis and staging of lung cancer are measurable. There is room for improvement in the diagnosis and staging of lung cancer


Assuntos
Humanos , Masculino , Feminino , Adulto , Pessoa de Meia-Idade , Idoso , Idoso de 80 Anos ou mais , Qualidade da Assistência à Saúde , Neoplasias Pulmonares/diagnóstico , Estadiamento de Neoplasias/normas , Espanha
16.
Rev. cuba. hematol. inmunol. hemoter ; 36(1): e1003, ene.-mar. 2020. graf
Artigo em Espanhol | LILACS, CUMED | ID: biblio-1126541

RESUMO

Introducción: Los estudios de imágenes son esenciales para la estadificación de los linfomas. La utilización de la imagen funcional que proporciona la tomografía por emisión de positrones con 18F-2-deoxi-2-fluoro-D-glucosa asociada a la tomografía computarizada ha cambiado fundamentalmente el concepto de estadificación y reestadificación de los linfomas. Constituye una prueba diagnóstica que ha ganado aceptación universal, sobre todo después de la publicación y adopción de las guías de Lugano. Objetivo: Analizar la importancia que tienen las imágenes que proporciona la tomografía por emisión de positrones con 18F-2-deoxi-2-fluoro-D-glucosa asociada a la tomografía computarizada en la estadificación actual de los linfomas. Métodos: Se realizó una revisión bibliográfica, en español y en inglés, de la última década. Se utilizaron los motores de búsqueda de Pubmed, Google y SciELO. Se recolectó y organizó la información siguiendo cronológicamente la aparición de las innovaciones para facilitar la estadificación de los linfomas. Análisis y síntesis de la información: Se hace un recorrido desde la introducción de la tomografía computarizada, la tomografía por emisión de positrones y la asociación de estas, hasta su aplicación en el estudio de los linfomas. Se describe la evolución de los sistemas de clasificación para los linfomas y la utilidad del empleo de la tomografía por emisión de positrones con 18F-2-deoxi-2-fluoro-D-glucosa asociada a la tomografía computarizada en la estadificación de los linfomas. Conclusiones: Es de gran importancia que, en el momento actual, el manejo óptimo de un paciente con linfoma ávido de 18F-2-deoxi-2-fluoro-D-glucosa incluya la estadificación inicial con tomografía por emisión de positrones asociada con tomografía computarizada. Esto permitirá hacer más precisa la etapificación inicial del paciente, optimizar su tratamiento y evaluación de la terapia implementada; así como un mejor pronóstico y evitar estudios invasivos(AU)


Introduction: Imaging studies are essential for staging of lymphomas. The usage of functional imaging provided by positron emission tomography with 18F-2-deoxy-2-fluoro-D-glucose combined with computed tomography has fundamentally changed the concept of staging and re-staging of lymphomas. It constitutes a diagnostic test that has gained universal acceptance, especially after the publication and adoption of the Lugano guidelines. Objective: To analyze the importance of the images provided by positron emission tomography with 18F-2-deoxy-2-fluoro-D-glucose combined with computed tomography in current staging of lymphomas. Methods: A bibliographic review was carried out, in Spanish and in English, within the last decade. We used the search engines of Pubmed, Google, and SciELO. The information was collected and organized by chronologically following the origin of the innovations that facilitate the staging of lymphomas. Information analysis and synthesis: An analysis is carried out from the introduction of computed tomography, positron emission tomography, and the combination of both, to their application in the study of lymphomas. We described the evolution of lymphoma classification systems and the usefulness of positron emission tomography with 18F-2-deoxy-2-fluoro-D-glucose combined with computed tomography for the staging of lymphomas. Conclusions: At the present time, it is of great importance for a patient with lymphoma needing 18F-2-deoxy-2-fluoro-D-glucose to receive optimal management of his or her condition, including initial staging with positron emission tomography combined with computed tomography. This will allow to make the initial staging of the patient more precise, to optimize his or her treatment and evaluation of the implemented therapy, as well as to obtain a better prognosis, avoiding invasive studies(AU)


Assuntos
Humanos , Masculino , Feminino , Tomografia Computadorizada com Tomografia por Emissão de Pósitrons/métodos , Linfoma/diagnóstico por imagem , Estadiamento de Neoplasias/normas
17.
Can J Surg ; 63(1): E57-E61, 2020 02 07.
Artigo em Inglês | MEDLINE | ID: mdl-32031765

RESUMO

Background: International guidelines recommend routine computed tomography (CT) of the chest for gastric cancer staging. In Asian countries, where the incidence of pulmonary metastases is less than 1%, some guidelines recommend chest CT only for gastroesophageal junction cancers. If the incidence of pulmonary metastases is also low in Canada, routine chest CT may not be beneficial. Methods: We performed a retrospective review of patients in northern Alberta with newly diagnosed gastric cancer from January 2010 to July 2016. The primary aim of the study was to determine the incidence of pulmonary metastases at the time of diagnosis in this population. A secondary aim was to identify potential predictors of pulmonary metastases. We reviewed CT reports for pulmonary metastases. Imaging data also included liver metastases, abdominal lymphadenopathy (> 1 cm), ascites and omental or peritoneal nodules. Other data recorded were age, sex, primary tumour location, histologic type and tumour grade. Results: Four hundred and sixty-two patients (311 men, 151 women) were included in the analysis. Pulmonary metastases were identified in 25 patients (5.4%) overall and in 11 of 299 patients (3.7%) whose primary cancer was not in the cardia. On univariate analysis the presence of liver metastases (odds ratio [OR] 7.72, 95% confidence interval [CI] 3.24­18.37, p < 0.001) and abdominal lymphadenopathy (OR 3.30, 95% CI 1.29­8.48, p = 0.01) was associated with an increased risk of pulmonary metastases. Liver metastases retained statistical significance on multivariate analysis (OR 6.17, 95% CI 2.53­15.03, p < 0.001). Conclusion: The incidence of pulmonary metastases at the time of gastric cancer diagnosis is higher in northern Alberta than previously reported in Asian studies. Abdominal lymphadenopathy and liver metastases confer an elevated risk of pulmonary metastases.


Assuntos
Neoplasias Pulmonares/diagnóstico por imagem , Neoplasias Pulmonares/secundário , Estadiamento de Neoplasias/normas , Radiografia Torácica/normas , Sistema de Registros , Neoplasias Gástricas/diagnóstico por imagem , Adulto , Idoso , Alberta/epidemiologia , Feminino , Humanos , Neoplasias Hepáticas/diagnóstico , Neoplasias Hepáticas/epidemiologia , Neoplasias Hepáticas/secundário , Neoplasias Pulmonares/epidemiologia , Linfadenopatia/diagnóstico , Linfadenopatia/epidemiologia , Masculino , Pessoa de Meia-Idade , Valor Preditivo dos Testes , Radiografia Torácica/estatística & dados numéricos , Sistema de Registros/estatística & dados numéricos , Estudos Retrospectivos , Risco , Neoplasias Gástricas/epidemiologia , Tomografia Computadorizada por Raios X/estatística & dados numéricos
18.
PLoS One ; 15(2): e0228501, 2020.
Artigo em Inglês | MEDLINE | ID: mdl-32012198

RESUMO

BACKGROUND: External validation of prognostic risk models is essential before they are implemented in clinical practice. This study evaluated the recently developed MEGNA score for survival prediction after resection of intrahepatic cholangiocarcinoma (ICC), with a focus on the direct comparison of its prognostic value to that of the current International Union Against Cancer (UICC)/American Joint Committee on Cancer (AJCC) Cancer staging system. MATERIAL AND METHODS: Between 1997 and 2018, 417 consecutive patients with ICC were referred to our tertiary care centre and were retrospectively identified out of a dedicated clinical database. Of this group, 203 patients underwent surgical resection and met the inclusion criteria. Multivariate analysis was performed to assess the predictors of the recently proposed MEGNA score regarding overall survival (OS). Concordance indices (C-indices) and integrated Brier scores (IBS) were calculated to assess the ability of both the MEGNA score and the current (8th) edition of the UICC/AJCC Cancer staging system to predict individual patient outcome. RESULTS: Stratification according to the MEGNA score resulted in a median OS of 34.5 months, 26.1 months, 21.5 months, and 16.6 months for MEGNA scores 0, 1, 2, and ≥3, respectively (log rank p < 0.001). However, of the five factors that contribute to the MEGNA score, age > 60 years was not a predictor for poor OS in our cohort. The C-index for the MEGNA score was 0.58, the IBS was 0.193. The 8th edition of the UICC/AJCC system performed slightly better, with a C-index of 0.61 and an IBS of 0.186. CONCLUSION: The ability of the MEGNA score to predict individual patient outcome was only moderate in this external validation. Its prognostic value did not reach that of the more widely known and used UICC/AJCC system. However, neither scoring system performed well enough to support clear-cut clinical decisions.


Assuntos
Neoplasias dos Ductos Biliares/diagnóstico , Colangiocarcinoma/diagnóstico , Oncologia/métodos , Estadiamento de Neoplasias/métodos , Idoso , Neoplasias dos Ductos Biliares/mortalidade , Neoplasias dos Ductos Biliares/patologia , Ductos Biliares Intra-Hepáticos/patologia , Colangiocarcinoma/mortalidade , Colangiocarcinoma/patologia , Estudos de Coortes , Feminino , Humanos , Agências Internacionais/normas , Masculino , Oncologia/normas , Pessoa de Meia-Idade , Estadiamento de Neoplasias/normas , Valor Preditivo dos Testes , Prognóstico , Projetos de Pesquisa/normas , Estudos Retrospectivos , Fatores de Risco , Análise de Sobrevida , Estados Unidos
19.
Zhonghua Wei Chang Wai Ke Za Zhi ; 23(1): 87-91, 2020 Jan 25.
Artigo em Chinês | MEDLINE | ID: mdl-31958938

RESUMO

Comprehensive treatment of gastric cancer is mainly based on the pathological staging. The T stage mainly depends on the accurate determination of the depth of the tumor invasion. The accurate T stage should be standardized pathological examination and continuous sectioning. N stage may be influenced by the number of lymph node examined. Insufficient lymph node examined may lead to stage migration. Therefore, standardizing lymph node dissection and lymph node harvest after surgery is important. M stage is mainly to improve the detection rate of peritoneal lavage cytology (CY), identify high risk factors for peritoneal metastasis, and optimize the prediction of peritoneal metastasis molecular markers, as a complementary methods of clinical examination. Currently, the quality of standardized pathological diagnosis of gastric cancer in China still needs to be improved. This article mainly elucidates the related studies and clinical experience of our center on how to do better in the optimization of gastric cancer TNM staging and pathological quality control.


Assuntos
Excisão de Linfonodo/normas , Linfonodos/patologia , Estadiamento de Neoplasias/normas , Neoplasias Gástricas/patologia , China , Humanos , Linfonodos/cirurgia , Estadiamento de Neoplasias/métodos , Fatores de Risco
20.
Can J Surg ; 63(1): E27-E34, 2020 01 22.
Artigo em Inglês | MEDLINE | ID: mdl-31967442

RESUMO

Background: Rectal cancer requires a multidisciplinary and multimodality treatment approach. Clinical practice guidelines (CPGs) provide a framework for delivering consistent, evidence-based health care. We compared provincial/territorial CPGs across Canada to identify areas of variability and evaluate their quality. Methods: We retrieved CPGs from Canadian organizations responsible for cancer care oversight and evaluated their quality and developmental methodology using the AGREE-II instrument. Recommendations for diagnostic and staging investigations, treatment by stage, and post-treatment surveillance of stage I­III rectal cancers were abstracted and compared. Results: We identified 7 sets of CPGs for analysis, varying in content, presentation, quality, and year last updated. Differences were noted in locoregional staging: 4 recommended magnetic resonance imaging over endorectal ultrasonography, 2 recommended either modality, and 3 specified scenarios for one over the other. Recommendations also varied for use of staging computed tomography of the chest versus chest radiography and for surgical management and indications for transanal excision. Recommendations for neoadjuvant therapy in stage II/III disease also differed: 3 guidelines recommended long-course chemoradiation over short-course radiation therapy alone, while 3 others recommended short-course radiation in specific clinical scenarios. Adjuvant chemotherapy for stage II/III disease was uniformly recommended, with variable protocols. The use of proctosigmoidoscopy and interval/duration of endoscopic post-treatment surveillance varied among guidelines. Conclusion: Canadian CPGs vary in their recommendations for staging, treatment, and surveillance of rectal cancer. Some of these differences reflect areas with limited definitive evidence. Consistent guidelines with uniform implementation across provinces/territories may lead to more equitable care to patients.


Assuntos
Quimiorradioterapia/normas , Procedimentos Cirúrgicos do Sistema Digestório/normas , Terapia Neoadjuvante/normas , Cuidados Pós-Operatórios/normas , Guias de Prática Clínica como Assunto/normas , Neoplasias Retais/diagnóstico por imagem , Neoplasias Retais/terapia , Canadá , Endossonografia/normas , Medicina Baseada em Evidências , Humanos , Imagem por Ressonância Magnética/normas , Estadiamento de Neoplasias/normas , Sigmoidoscopia/normas
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...